What Clamisin Treats: Main Uses and Benefits

Clamisin (amoxicillin and clavulanic acid) is an antibiotic applied across domains where additional symptomatic support is needed for bacterial infections. This combination is commonly used to help with conditions that produce significant symptomatic burden in several key areas. It is relevant for easing symptoms linked to infections of the ears, lungs, sinus, skin, and urinary tract. This treatment may be part of symptomatic management for a range of conditions characterized by periods of heightened symptoms and is generally used in areas where short-term symptom management is appropriate.

The medicine is often used in clinical settings that involve acute or unstable symptom patterns, where the infectious process creates noticeable physiological strain. The formulation assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations seen in conditions involving episodic or fluctuating manifestations.

“This medicine contributes to improved comfort during periods of heightened symptoms and is applied in scenarios where additional management of discomfort is required.”

This medicine may assist with easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Relief for Symptoms related to physical discomfort (e.g., pain, fever, swelling) may be part of symptomatic management during phases of increased distress or discomfort.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Rules for Clamisin (Clarithromycin)

Regulatory documents define strict population eligibility for Clamisin based on age, organ function, and pre-existing conditions. These rules determine who is allowed to use the medicine, who must use it under restriction, and who is absolutely prohibited from use.

Contraindicated Populations

Clamisin is contraindicated in patients with a known hypersensitivity to clarithromycin or any macrolide antibiotic. Absolute prohibition also applies to individuals with a history of QT prolongation, ventricular cardiac arrhythmia, or those with severe hepatic failure combined with renal impairment.

Restricted and Non-Established Use

Age: The medicine is not suitable for children under 12 years in tablet form, and its safety and efficacy are not established in infants younger than 6 months. Older adults may require caution due to increased risk of renal or cardiac issues.

Organ Function: Use is restricted for patients with severe renal impairment; a dose adjustment is typically required. Caution is also advised in cases of impaired hepatic function.

Pregnancy and Lactation: Use during pregnancy is not recommended, particularly in the first trimester, unless a medical authority determines the benefit outweighs the risk. Clarithromycin is excreted into breast milk.

Interactions with other medicines and products

Clamisin (clarithromycin) is primarily metabolized by the CYP3A4 enzyme system and acts as an inhibitor of this enzyme. Coadministration with drugs that rely heavily on CYP3A4 for clearance can significantly increase their plasma concentrations, potentially leading to serious or life-threatening reactions.

Contraindicated Combinations:

• Colchicine: Concomitant use with Clamisin is contraindicated, especially in patients with impaired kidney or liver function. This combination can result in fatal toxicity due to dangerously elevated colchicine levels, demanding immediate avoidance.

Other Significant Interactions and Precautions:

• Oral Anticoagulants: Concomitant use with oral anticoagulants, such as warfarin, can potentiate their effects, increasing the risk of severe bleeding. Frequent monitoring of coagulation parameters is required.
• Theophylline and Cilostazol: Clamisin may increase the systemic exposure of these agents, requiring a dosage reduction for the coadministered drug and close monitoring for toxicity.
• Antiretroviral Agents: When used as part of triple therapy, the combination with certain antiretroviral drugs, such as Atazanavir or Nelfinavir, may lead to substantially decreased concentrations of the antiretroviral agent, making coadministration generally not recommended.
• Tacrolimus: Use with Clamisin requires frequent monitoring of whole blood trough concentrations of Tacrolimus, as its serum levels may increase significantly.

The active ingredient in Clamisin, Clarithromycin, produces defined physiological changes through two core mechanistic domains. The primary action is a highly targeted molecular interaction within the bacterial cell where Clarithromycin acts as a direct inhibitor. It binds specifically and reversibly to the 23S rRNA within the 50S ribosomal subunit . This binding physically obstructs the exit tunnel used by nascent proteins, effectively blocking the ribosome's translocation and halting the elongation of the peptide chain. The resulting physiological effect is a profound bacteriostatic arrest of the bacterial population, inhibiting its proliferation within host tissues. The drug's overall effect is supported by the active metabolite, 14-hydroxyclarithromycin, which shares the identical mechanism of protein synthesis inhibition, providing an additive antimicrobial contribution. Separately, Clarithromycin also engages a secondary mechanism that involves the downregulation of pro-inflammatory cytokines (like IL-6 and IL-8) in host tissues. This activity modulates inflammatory signaling, contributing to the regulation of the host's physiological response concurrent with the antimicrobial effect.

Clamisin (Clarithromycin) is administered through established routes, including oral forms (immediate-release tablets, extended-release tablets, and oral suspension) and Intravenous (IV) Infusion. The standard adult oral dosing regimen for immediate-release tablets is typically 250 mg twice daily, while the extended-release formulation is administered as 1000 mg once daily. Treatment courses generally range between 6 and 14 days to complete the course.

The proper administration of the medicine is conditional on its specific form. The extended-release tablet must be taken with food to ensure correct absorption, whereas the immediate-release tablet and oral suspension can be taken independently of meals. Procedural constraints dictate that the extended-release tablet must be swallowed whole and cannot be crushed, broken, or chewed. The liquid oral suspension requires the granules to be reconstituted with water and shaken prior to use, as specified in the product instructions.

Dosing is subject to adjustment based on patient physiology. For individuals with severe renal impairment (CrCl < 30 mL/min), the total daily dosage must be reduced by one-half. Furthermore, for children under 12, the tablet forms are typically substituted with the oral suspension at a weight-based dose, following a specific administration pattern for pediatric patients.

Clamisin: Recent Clinical Evidence

Evidence for Use in Acute Bacterial Infections

Research on Clamisin (Clarithromycin) has primarily involved short-term, comparative Randomized Controlled Trials (RCTs) designed to evaluate its use in studies related to approved acute bacterial illnesses, such as respiratory tract and skin infections. These studies aimed to measure the Bacteriological Eradication Rate and Clinical Cure Rate, observing changes in symptom expression over short, defined intervals. Findings indicate that research is still exploring the factor of growing macrolide resistance profiles.

Evidence for Use in Managing H. pylori and Ulcer Recurrence

Clamisin was evaluated in studies as part of a multi-drug combination therapy to eradicate Helicobacter pylori, which was studied in relation to reducing duodenal ulcer recurrence. Studies reported patterns in the Eradication Rate and the frequency of ulcer recurrence in observed groups. Research highlights challenges in areas where the H. pylori pathogen exhibits macrolide resistance, and long-term effects on the durability of ulcer non-recurrence beyond one year are not fully established.

Evidence for Use in Specific High-Risk Infections

Dedicated research explored Clamisin's use in highly specialized settings involving immunocompromised populations, such as adults and children with advanced HIV infection who have Disseminated Mycobacterium avium Complex (MAC) Infection. Studies monitored Clinical Response and the assessment of Overall Survival rates. Research focused on MAC is highly specialized, meaning results apply only to the specific populations studied.

Long-Term Studies and Extended Follow-up

Research has explored long-term post-treatment outcomes, primarily through one prospective, placebo-controlled trial (CLARICOR) that extended observation for up to 10 years in patients with stable coronary heart disease. This long-term observation was associated with specific changes measured during the study period, where the trial reported the long-term assessment of mortality rates in that group. Comparative evidence is lacking for long-term outcomes in patients without pre-existing heart disease.

Evidence in Specialized Populations and Research Uncertainty

Studies have included pediatric patients in trials for acute ear and respiratory infections, with findings described patterns in clinical response. However, data for certain groups, such as pregnant or breastfeeding populations, remain insufficient. Overall, evidence quality varies across studies, and research does not determine whether an individual will respond similarly to the group patterns observed.

Key Studies & References

1. WHO Model List of Essential Medicines (World Health Organization)

Storage and Disposal Requirements

Clamisin (clarithromycin) must be stored and handled according to specific conditions defined in official regulatory labeling to ensure stability and safety.

Storage Conditions

The tablets and granules must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original, tightly closed container and protected from moisture and light. The prepared oral suspension must not be refrigerated or frozen and is stable for 14 days after reconstitution, after which it must be discarded.

Disposal Instructions

All unused or expired Clamisin should be disposed of using a drug take-back program. If this is unavailable, it should be mixed with an unpalatable substance (like coffee grounds or dirt) and placed in a sealed bag before being thrown into the household trash. The medicine must always be kept out of the reach and sight of children.